Literature DB >> 10910900

In vivo generation of human dendritic cell subsets by Flt3 ligand.

E Maraskovsky1, E Daro, E Roux, M Teepe, C R Maliszewski, J Hoek, D Caron, M E Lebsack, H J McKenna.   

Abstract

Dendritic cells (DCs) represent a family of ontogenically distinct leukocytes involved in immune response regulation. The ability of DCs to stimulate T-cell immunity has led to their use as vectors for immunotherapy vaccines. However, it is unclear whether and to what degree in vitro-generated DCs are representative of DCs that develop in vivo. Treatment of mice with human Flt3 ligand (FL) dramatically increases the number of DCs. We report here that administration of FL to healthy human volunteers increased the number of circulating CD11c(+ )IL-3Ralpha(low) DC (mean 44-fold) and CD11c(-) IL-3Ralpha(high) DC precursors (mean 12-fold). Moreover, the CD11c(+ )DCs were efficient stimulators of T cells in vitro. Thus, FL can expand the number of circulating, functionally competent human DCs in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10910900

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

1.  Progress in cancer vaccines by enhanced self-presentation.

Authors:  S R Riddell
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

Review 2.  The plasmacytoid monocyte/interferon producing cells.

Authors:  Fabio Facchetti; William Vermi; David Mason; Marco Colonna
Journal:  Virchows Arch       Date:  2003-10-28       Impact factor: 4.064

Review 3.  Dendritic Cell-Based Cancer Vaccines.

Authors:  Patricia M Santos; Lisa H Butterfield
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

4.  Synergy between rapamycin and FLT3 ligand enhances plasmacytoid dendritic cell-dependent induction of CD4+CD25+FoxP3+ Treg.

Authors:  Moanaro Biswas; Debalina Sarkar; Sandeep R P Kumar; Sushrusha Nayak; Geoffrey L Rogers; David M Markusic; Gongxian Liao; Cox Terhorst; Roland W Herzog
Journal:  Blood       Date:  2015-04-01       Impact factor: 22.113

5.  Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice.

Authors:  H W Wang; W Yang; J Y Lu; G Tian; F Li; X H Wang; J R Kang; Y Yang
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

6.  Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant.

Authors:  Douglas G McNeel; Keith L Knutson; Kathy Schiffman; Donna R Davis; Dania Caron; Mary L Disis
Journal:  J Clin Immunol       Date:  2003-01       Impact factor: 8.317

Review 7.  Plant-derived polysaccharides activate dendritic cell-based anti-cancer immunity.

Authors:  Siambi Kikete; Li Luo; Beitian Jia; Li Wang; Gregory Ondieki; Yuhong Bian
Journal:  Cytotechnology       Date:  2018-03-19       Impact factor: 2.058

8.  Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

Authors:  N Anandasabapathy; G Breton; A Hurley; M Caskey; C Trumpfheller; P Sarma; J Pring; M Pack; N Buckley; I Matei; D Lyden; J Green; T Hawthorne; H C Marsh; M Yellin; T Davis; T Keler; S J Schlesinger
Journal:  Bone Marrow Transplant       Date:  2015-04-27       Impact factor: 5.483

9.  Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV- and SHIV-infected macaques.

Authors:  R Keith Reeves; Qing Wei; Jackie Stallworth; Patricia N Fultz
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

10.  Generation and characterization of chicken bone marrow-derived dendritic cells.

Authors:  Zhiguang Wu; Lisa Rothwell; John R Young; Jim Kaufman; Colin Butter; Pete Kaiser
Journal:  Immunology       Date:  2009-05-15       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.